Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elpida in Healthy HIV-Uninfected Volunteers
NCT05204121Phase 1Completed
- Sponsor
- Viriom Inc
- Start
- Dec 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of depulfavirine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Viriom Inc. Primary endpoint: Incidence of Adverse Events and Serious Adverse Events at 77 days. Started Dec 2018; status: completed.
02
Drugs
depulfavirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05204121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05204121.